≋CHEST[™]

Culture-Negative Severe Sepsis Nationwide Trends and Outcomes



Shipra Gupta, MD; Ankit Sakhuja, MD; Gagan Kumar, MD; Eric McGrath, MD; Rahul S. Nanchal, MD; and Kianoush B. Kashani, MD, FCCP

BACKGROUND: Although 28% to 49% of severe sepsis hospitalizations have been described as being "culture negative," there are very limited data on the epidemiology and outcomes of those with culture-negative severe sepsis (CNSS). The objectives of this study were to investigate the proportion and trends of CNSS and its association with mortality.

METHODS: Using the Nationwide Inpatient Sample (NIS) database from 2000 to 2010, we identified adults hospitalized with severe sepsis. Those without any specific organism codes were identified as "with CNSS." We examined the proportion of CNSS hospitalizations and rates of mortality associated with it. We also assessed the independent effect of CNSS on mortality.

RESULTS: Of 6,843,279 admissions of patients with severe sepsis, 3,226,406 (47.1%) had culture-negative results. The age-adjusted proportion of CNSS increased from 33.9% in 2000 to 43.5% in 2010 (P < .001). Those with CNSS had more comorbidities, acute organ dysfunction (respiratory, cardiac, hepatic, and renal dysfunction), and in-hospital mortality (34.6% vs 22.7%; P < .001), although acute kidney injury requiring dialysis was less frequent (5.3% vs 6.1%; P < .001). CNSS was an independent predictor of mortality in those with severe sepsis (OR, 1.75; 95% CI, 1.72-1.77).

CONCLUSIONS: CNSS among hospitalized patients is common, and its proportion is on the rise. CNSS is associated with greater acute organ dysfunction and mortality. Having CNSS is an independent predictor of death. CHEST 2016; 150(6):1251-1259

KEY WORDS: culture; mortality; sepsis

Pulmonary and Critical Care Medicine, Department of Medicine (Dr Kashani), Mayo Clinic, Rochester, MN.

DOI: http://dx.doi.org/10.1016/j.chest.2016.08.1460

ABBREVIATIONS: CCI = Charlson comorbidity index; CNSS = culturenegative severe sepsis; CPSS = culture-positive severe sepsis; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; NIS = Nationwide Inpatient Sample; SIRS = systemic inflammatory response syndrome

AFFILIATIONS: Division of Infectious Diseases, Department of Pediatrics (Drs Gupta and McGrath), Children's Hospital of Michigan, Detroit, MI; Division of Nephrology, Department of Internal Medicine (Dr Sakhuja), University of Michigan, Ann Arbor, MI; Department of Critical Care (Dr Kumar), Phoebe Putney Memorial Hospital, Albany, GA; Department of Pulmonary and Critical Care Medicine (Dr Nanchal), Medical College of Wisconsin, Milwaukee, WI; Division of

FUNDING/SUPPORT: The authors have reported to *CHEST* that no funding was received for this study.

CORRESPONDENCE TO: Ankit Sakhuja, MBBS, Division of Nephrology, Department of Internal Medicine, University of Michigan, 3914 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109; e-mail: asakhuja@alumni.mcw.edu

Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Severe sepsis is one of the leading causes of death in the Unites States and results in a significant health-care burden.¹ Recent epidemiologic data have shown that the incidence of severe sepsis has increased over the past decade.² Although sepsis-associated mortality has been on the decline, it continues to affect more than one-fourth of those admitted to the hospital with severe sepsis.²

The clinical diagnosis of sepsis is based on the manifestations of the systemic inflammatory response syndrome (SIRS) in the presence of proven or suspected infection.³ Although an infectious cause is fundamental to the definition of sepsis, in many cases isolation of specific organisms by culture remains challenging. Severe sepsis without a microbiologically documented infection is called "culture-negative severe sepsis" (CNSS). In a significant proportion of severe sepsis episodes, no specific organism can be identified.⁴⁻⁹ Even in rigorous randomized controlled trials, approximately one-fourth of patients with severe sepsis remain culture negative.¹⁰ In fact, a growing literature suggests a differential risk of mortality depending on the specific organism associated with a severe sepsis episode.¹¹⁻¹³

Methods

Study Design

We designed a retrospective study using data from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (NIS) from 2000 to 2010. NIS is the largest all-payer inpatient care database publicly available in the United States. It includes data from a 20% stratified sample of US community hospitals.¹⁵ Each hospitalization in this database is treated as an individual entry. The database contains information about age, race, and sex, along with primary insurance, hospital characteristics and teaching status, location (rural vs urban), size of the hospital, and hospital region. In addition, each hospitalization entry provides information about principal, secondary, and procedural diagnoses. As the current study was a retrospective analysis of a hospital-based discharge data set that is available publicly from the Agency for Healthcare Research and Quality, it did not require institutional review board approval.

Study Population

We included all hospitalizations with severe sepsis during the study period. In accordance with the previous literature,^{2,4,16} we defined severe sepsis as the use of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for severe sepsis or septic shock, septicemia, bacteremia, or fungemia, with dysfunction of at least one organ. We used ICD-9-CM codes to identify specific organisms and infection sites associated with hospitalizations. We have provided the codes used in e-Tables 1-4. Severe sepsis hospitalizations that were not associated with codes for any specific organisms were identified as CNSS hospitalizations.

Various multicenter studies have reported the proportion of CNSS admissions to be between 28% and 49% of all patients with severe sepsis.⁴⁻⁹ Despite the abundance of CNSS, there is a remarkable paucity of investigations elucidating its epidemiology and outcomes. One previous study, limited by a small sample size and single-center design, found > 40% of cases of severe sepsis to be culturenegative.¹⁴

It is difficult to discern the reasons for culture negativity; however, some plausible explanations include administration of antibiotics before obtaining cultures, infections with fastidious organisms, and noninfectious causes of SIRS inappropriately deemed CNSS. In this regard, CNSS may represent a unique cohort of individuals. Therefore, understanding the epidemiology and outcomes of CNSS is of particular importance for the design of future clinical trials and for qualityimprovement purposes. We conducted this study to understand the incidence, trends, and outcomes of patients hospitalized with CNSS. Our goals were to (1) investigate the proportion and trends of CNSS among severe sepsis hospitalizations and (2) investigate if being culture negative is an independent predictor of death in those with severe sepsis.

Study Variables

We used NIS variables to determine demographic characteristics (age, sex, and race), hospital characteristics (teaching status, location, bed size, and region), and primary payer. We divided hospitals into tertiles based on the annual volume of severe sepsis discharges (< 227, 227-474, and > 474 per year). The burden of comorbid diseases was identified using Deyo's modification of the Charlson comorbidity index (CCI).¹⁷ We identified individuals receiving mechanical ventilation using ICD-9-CM procedure codes 96.70, 96.71, and 96.72. We defined septic shock as either the presence of the ICD-9-CM code for septic shock or a combination of severe sepsis and acute cardiovascular dysfunction.

Outcomes

Our primary outcomes of interest were the proportion of patients with severe sepsis who had negative culture results and the trend of CNSS hospitalizations. Our secondary outcomes of interest were the incidence and trends of mortality associated with CNSS in comparison to those associated with CPSS. In addition, we investigated if culture-negative results are an independent predictor of death in those with severe sepsis.

Statistical Analysis

We generated national estimates of the number of overall severe sepsis hospitalizations using weights provided in the NIS database. The χ^2 test was used to compare categorical variables, and linear regression was used to assess the significance of trends over time. Direct standardization of the age of the 2000 US standard population was performed to estimate the age-adjusted incidence of severe sepsis and mortality. 18 Stata, version 14.0 (StataCorp LP) was used for all statistical analyses.

We used a multivariable logistic regression model to estimate the odds of all-cause inpatient mortality. All clinically relevant variables were included in the final multivariable model, which was adjusted for age; sex; race; primary payer; CCI; hospital teaching status, location, region, volume (small, medium, and large), and bed size; individual organ dysfunctions; respiratory failure requiring mechanical ventilation; and, finally, the year of admission. Interactions of CNSS status were assessed with year of admission, age group, and hospital teaching status. We then used a linear combination of estimates to predict the independent effect of CNSS on mortality for specific age groups.

Results

Proportion and Trends of CNSS

There were 6,843,279 (95% CI, 6,587,649-7,098,909) admissions in patients with severe sepsis in the period studied, 3,226,406 (95% CI, 3,102,039-3,350,773) of which were CNSS. The age-adjusted proportion of CNSS hospitalizations increased from 33.9% of all severe sepsis hospitalizations in 2000 to 43.5% of these hospitalizations in 2010 (*P* for trend < .001) (Fig 1).

Patient Characteristics Based on Culture Status

The proportion of **CNSS** hospitalizations was higher in those < 1 year or \geq 70 years of age and in white patients. In comparison with patients with CPSS, those with **CNSS** were more often admitted to nonteaching hospitals (55% vs 50.6%; *P* < .001), had a higher comorbidity burden as evidenced by a higher CCI (28.2% vs 26.5% with CCI score > 3; *P* < .001), a higher number of acute organ system dysfunctions (27.0% vs 23.1% with more than three acute organ system dysfunctions; *P* < .001), and were more likely to have acute respiratory failure (52.1% vs 46.7%; *P* < .001), need mechanical ventilator support (37.7% vs 35.7%; *P* < .001), and have septic shock (41.1% vs 35.5%; *P* < .001), cardiovascular failure, hepatic failure, and metabolic dysfunction (Table 1). Infections



Figure 1 – Trends of culture-negative severe sepsis (CNSS) hospitalizations.

Missing data was < 1% for all variables except race, which was missing in approximately 20% of observations. Casewise deletion was used to handle missing data. To ensure that this methodology of handling missing data did not affect our results, we performed a sensitivity analysis by including missing values of race under the "missing" category for race in the logistic regression.

To further assess the robustness of our results we performed four additional sensitivity analyses, the details of which we have provided in e-Appendix 1.

identified at common sites, as shown in Table 2, were more commonly associated with CPSS.

Mortality Based on Culture Status

Unadjusted mortality was higher in those with CNSS compared with those with CPSS (34.6% vs 22.7%; P < .001). Although age-adjusted mortality declined in both patients with CPSS and those with CNNS, it was still significantly higher in CNSS than in CPSS (Fig 2). After multivariable adjustment, culture-negative status was an independent predictor of mortality in those with severe sepsis (OR, 1.75; 95% CI, 1.72-1.77) (Table 3). There was an 11% improvement in the odds of death with each passing year (OR, 0.89; 95% CI, 0.89-0.90). On exploratory analysis, the interaction term between culture-negative status and year of admission was not significant (interaction P = .3), suggesting similar odds for improvement in mortality over the years, regardless of culture status. However, CNSS had a differential effect on mortality for different age groups, as evidenced by a significant interaction term between the variable for age groups and culture-negative status (interaction P < .001) (e-Fig 2). The interaction term between CNSS and hospital teaching status was also significant (interaction P = .02), with CNSS being associated with a 72% increase in the odds of death in teaching hospitals (OR, 1.72; 95% CI, 1.68-1.76) vs 78% in nonteaching hospitals (OR, 1.78; 95% CI, 1.75-1.81).

Sensitivity Analyses

Culture-negative status was associated with a 74% increased odds of mortality in those with severe sepsis (OR, 1.74; 95% CI, 1.72-1.76) in the analysis that used missing values of race as a "missing" category for the variable of race in the regression model (e-Table 5). Culture-negative status continued to be an independent predictor of mortality in the propensity-matched sample (OR, 1.75; 95% CI, 1.73-1.76) (e-Table 6). Culturenegative status was also an independent predictor of death when those with acute cardiac dysfunction were excluded from the cohort (OR, 1.68; 95% CI, 1.65-1.71) (e-Table 7).

| TABLE 1 | Baseline | Characteristics | of Patients | Hospitalized | With Severe | Sepsis |
|---------|----------|-----------------|-------------|--------------|-------------|--------|
|---------|----------|-----------------|-------------|--------------|-------------|--------|

| Characteristic | CNSS, % (n = 3,226,406) | CPSS, % (n = 3,616,873) | P Value |
|--|----------------------------|----------------------------|---------|
| Age group, y | | | < .001 |
| < 1 | 2.5 | 2.0 | |
| 1-4 | 0.3 | 0.6 | |
| 5-9 | 0.2 | 0.3 | |
| 10-14 | 0.2 | 0.4 | |
| 15-19 | 0.5 | 0.7 | |
| 20-29 | 1.8 | 2.3 | |
| 30-39 | 3.4 | 3.9 | |
| 40-49 | 7.3 | 8.4 | |
| 50-59 | 13.4 | 14.5 | |
| 60-69 | 17.5 | 18.1 | |
| 70-79 | 23.0 | 22.7 | |
| ≥ 80 | 29.9 | 26.0 | |
| Sex | | | < .001 |
| Male | 50.1 | 50.9 | |
| Race | | | < .001 |
| White | 55.7 | 55.8 | |
| Black | 11.6 | 12.4 | |
| Hispanic | 7.4 | 7.7 | |
| Asian | 2.1 | 2.3 | |
| Native American | 0.5 | 0.5 | |
| Other | 2.1 | 2.3 | |
| Missing | 20.6 | 19.0 | |
| Primary payer | | | < .001 |
| Medicare | 64.5 | 61.7 | |
| Medicaid | 11.1 | 12.6 | |
| Private | 18.7 | 19.9 | |
| Self-pay | 3.1 | 3.1 | |
| No charge | 0.3 | 0.3 | |
| Other | 2.3 | 2.3 | |
| Charlson comorbidity index score | | | < .001 |
| < 3 | 71.8 | 73.5 | |
| 3-4 | 16.2 | 15.8 | |
| ≥ 5 | 12.0 | 10.7 | |
| Respiratory dysfunction | 52.1 | 46.7 | < .001 |
| Cardiac dysfunction | 41.1 | 35.5 | < .001 |
| Hepatic dysfunction | 5.9 | 5.0 | < .001 |
| Acute kidney injury | 49.0 | 48.5 | < .001 |
| Acute kidney injury requiring dialysis | 5.3 | 6.1 | < .001 |
| Hematologic dysfunction | 16.1 | 19.8 | < .001 |
| Metabolic dysfunction | 18.5 | 15.1 | < .001 |
| Neurologic dysfunction | 13.0 | 13.0 | .9 |
| Septic shock | 41.1 | 35.5 | < .001 |
| Mechanical ventilation use | 37.7 | 35.7 | < .001 |

(Continued)

TABLE 1] (Continued)

| Characteristic | CNSS, % (n = 3,226,406) | CPSS, % (n = 3,616,873) | <i>P</i> Value |
|--------------------------|----------------------------|----------------------------|----------------|
| Hospital teaching status | | | < .001 |
| Teaching | 45 | 49.4 | |
| Hospital bed size | | | .1 |
| Small | 11.0 | 11.5 | |
| Medium | 24.6 | 24.1 | |
| Large | 64.4 | 64.5 | |
| Hospital volume | | | .6 |
| Small | 32.8 | 33.1 | |
| Medium | 34.0 | 33.8 | |
| Large | 33.2 | 33.1 | |
| Hospital location | | | < .001 |
| Urban | 89.3 | 91.1 | |
| Hospital region | | | < .001 |
| Northeast | 18.7 | 20.8 | |
| Midwest | 20.8 | 21.2 | |
| South | 41.8 | 37.3 | |
| West | 18.8 | 20.7 | |
| Year of admission | | | < .001 |
| 2000 | 4.0 | 5 | |
| 2001 | 4.7 | 5.5 | |
| 2002 | 5.5 | 6.2 | |
| 2003 | 6.8 | 6.7 | |
| 2004 | 7.6 | 7.8 | |
| 2005 | 8.8 | 8.7 | |
| 2006 | 9.7 | 9.4 | |
| 2007 | 10.9 | 10.6 | |
| 2008 | 13.2 | 12.3 | |
| 2009 | 13.5 | 13.6 | |
| 2010 | 15.3 | 14.2 | |

CNSS = culture-negative severe sepsis; CPSS = culture-positive severe sepsis.

| Infection Site | CNSS, % (n = 3,226,406) | CPSS, % (n = 3,616,873) | P Value |
|--|----------------------------|----------------------------|---------|
| Lung infection | 33.5 | 37.3 | < .001 |
| Renal infection | 26.4 | 37.7 | < .001 |
| Gastrointestinal infection | 14.3 | 21.6 | < .001 |
| Skin and subcutaneous tissue infection | 6.2 | 7.5 | < .001 |
| Joint/bone infection | 1.4 | 3.0 | < .001 |
| Infective endocarditis | 0.5 | 2.5 | < .001 |
| Meningitis, intracranial and intraspinal abscess | 0.3 | 1.5 | < .001 |
| Others | 33.7 | 20.4 | < .001 |

TABLE 2] Infection Sites Based on Culture Status

See Table 1 legend for expansion of abbreviations.



Figure 2 – *Trends of mortality in patients with severe sepsis by culture status.*

Similarly, in the cohort that included only patients who survived the first 3 days of hospitalization, having culturenegative status was still a significant predictor of mortality (OR, 1.26; 95% CI, 1.24-1.28) (e-Table 8). Finally, when only unique observations were used, there was still an increase in the age-adjusted proportion of CNSS over the years and a culture-negative status was associated with increased odds of mortality (OR, 1.77; 95% CI, 1.74-1.80) (e-Fig 3, e-Table 9).

Discussion

To the best of our knowledge, this is the first study looking at the epidemiology and outcomes of CNSS in the US population. Using nationally representative data, we show that the proportion of CNSS among patients with sepsis has grown steadily over the past decade such that by the year 2010, 49% of severe sepsis hospitalizations were culture negative. During the period of our study, the number of CNSS hospitalizations rose at a rate of 28.1% per year; in contrast, the total number of severe sepsis hospitalizations rose by 22.3% per year. This is particularly remarkable, because if the current rate continues, CNSS will constitute the predominant form of severe sepsis in the near future. CNSS is less common when a specific source of infection can be identified. Further, we found that in-hospital all-cause mortality rates associated with CNSS were significantly higher than those associated with CPSS. This difference persisted after multivariable adjustment; the diagnosis of CNSS conferred a 75% excess risk of death compared with CPSS.

Phua et al¹⁴ characterized the frequency and associated mortality of CNSS and found that 41.5% of admissions with severe sepsis were culture negative. Further, in their study, patients who were culture negative had a lower severity of illness scores, fewer comorbid conditions, and lower mortality than culture-positive patients. Although

the proportion of patients with CNSS in our study is remarkably similar to that of Phua et al's study, we found a higher burden of comorbid disease and higher mortality rates in our culture-negative cohort. These differences are likely secondary to differences in sample size, patient population, geographic location, lack of information regarding the means of diagnosis (eg, procalcitonin, polymerase chain reaction techniques) and the multicentricity of our data. The study by Phua et al¹⁴ was conducted at a single-center university hospital, whereas our study included multiple hospitals with varying levels and standards of care. In addition, the patients included in our study were older (mean age of patients with CNSS and those with CPSS was 66.6 and 64.8 years, respectively, compared with 62 and 64 years, respectively, in their study). Although we did not have access to granular data to generate acute illness scores, the total number of acute organ dysfunctions was higher in the CNSS group (27.0% vs 23.1%; P < .001), suggesting a higher acuity of illness in the CNSS cohort. Another interesting finding of our study was that when compared with CPSS, acute kidney injury requiring dialysis was less frequent in individuals with CNSS, although overall acute kidney injury was higher. This could reflect the perceptions of patients, family, and providers that may lead to the lesser use of dialysis in this cohort because of their higher complexity and poorer outcomes.

With the implementation of Surviving Sepsis Campaign guidelines, studies have shown improvement in the proportion of blood being drawn for cultures before administration of antibiotics.^{19,20} This should have been expected to improve culture positivity rates for these admissions; however, our results suggest a decrease in culture positivity rates over time. The potential reasons for this discrepancy include aggressive empirical outpatient therapy of infections, early administration of antibiotic therapy before cultures are drawn in patients in whom severe sepsis is recognized, and readmissions of those with severe sepsis. Other potential explanations include increasing infections with viruses, especially in immunocompromised hosts, that may cause a severe sepsis-like picture and undercoding of specific organisms by coders unless it is specified in the physician note.

We also found that mortality associated with severe sepsis was significantly higher in those with CNSS. This difference in mortality persisted after multivariable adjustment and several sensitivity analyses. The odds of increased mortality was seen in both teaching and

| Characteristic OR 95% CI Culture status Reference Negative 1.75 1.72-1.77 Age group, y Reference 20-29 Reference < 1 0.58 0.52-0.64 1.4 1-4 0.71 0.62-0.81 5.9 5-9 0.73 0.63-0.85 10-14 0.85 0.75-0.97 15-19 0.79 0.71-0.87 30-39 1.18 1.12-1.24 40-49 1.40 1.34-1.47 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 Hore Sex 1.01-1.03 Race Internet Male Reference Female 1.02 1.01-1.03 Race Internet White Reference Internet Internet Internet Internet Black 1.00 0.97-1.02 Internet Internet Internet | • | | | |
|---|-------------------------------------|-----------|-------------|--|
| Culture status Reference Negative 1.75 1.72-1.77 Age group, y Image and the state of the | Characteristic | OR | 95% CI | |
| Positive Refere Negative 1.75 1.72-1.77 Age group, y Image and the second se | Culture status | | | |
| Negative 1.75 1.72-1.77 Age group, y | Positive | Refe | rence | |
| Age group, y Reference <1 | Negative | 1.75 | 1.72-1.77 | |
| 20-29 Reference <1 | Age group, y | | | |
| < 1 | 20-29 | Refe | rence | |
| 1-4 0.71 0.62-0.81 5-9 0.73 0.63-0.85 10-14 0.85 0.75-0.97 15-19 0.79 0.71-0.87 30-39 1.18 1.12-1.24 40-49 1.40 1.34-1.47 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex 0 4.80 Male Referme Female 1.02 1.01-1.03 Race 1.02 1.01-1.03 White Referme 1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer 1.02 1.12 Medicaid 1.09 1.92-1.36 Other 1.20 1.12-1.36 Other 1.20 1.12-1.36 Other 1.20 1.12-1.13 | < 1 | 0.58 | 0.52-0.64 | |
| 5-9 0.73 0.63-0.85 10-14 0.85 0.75-0.97 15-19 0.79 0.71-0.87 30-39 1.18 1.12-1.24 40-49 1.40 1.34-1.47 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex 0.101 1.01-1.03 Race 1.02 1.01-1.03 Race 1.02 1.01-1.03 White Ref= Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer 1.02 1.12 Medicaid 1.09 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 No charge | 1-4 | 0.71 | 0.62-0.81 | |
| 10-14 0.85 0.75-0.97 15-19 0.79 0.71-0.87 30-39 1.18 1.12-1.24 40-49 1.40 1.34-1.47 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex | 5-9 | 0.73 | 0.63-0.85 | |
| 15-19 0.79 0.71-0.87 30-39 1.18 1.12-1.24 40-49 1.40 1.34-1.47 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex - - Male Ref - Female 1.02 1.01-1.03 Race - - White Ref - Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer - - Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.13 score (base 0) - 1.12-1.13 s | 10-14 | 0.85 | 0.75-0.97 | |
| 30-39 1.18 1.12-1.24 40-49 1.40 1.34-1.47 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex 0 4.80 4.53-5.09 Sex 1.02 1.01-1.03 Race 1.02 1.01-1.03 Race 0.93 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer Medicare Ref= Medicare 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 Score (base 0) Respiratory dysfunction 3 | 15-19 | 0.79 | 0.71-0.87 | |
| $40-49$ 1.40 $1.34-1.47$ $50-59$ 1.66 $1.58+1.75$ $60-69$ 2.10 $1.99-2.22$ $70-79$ 2.95 $2.79-3.12$ ≥ 80 4.80 $4.53-5.09$ Sex $ -$ Male Ref= $-$ Female 1.02 $1.01-1.03$ Race 1.02 $1.01-1.03$ White Ref= $-$ Black 1.00 $0.97-1.02$ Hispanic 0.96 $0.93-0.99$ Asian 0.97 $0.88-0.98$ Native American 0.97 $0.89-1.05$ Other 1.00 $0.95-1.04$ Primary payer $ -$ Medicare Ref $-$ Medicare 1.109 $1.06-1.12$ Private 1.00 $0.98-1.02$ Self-pay 1.32 $1.25-1.39$ No charge 1.18 $1.02-1.36$ Other 1.20 $1.12-1.13$ Score (base 0) $Ref=$ $Ref =$ | 30-39 | 1.18 | 1.12-1.24 | |
| 50-59 1.66 1.58-1.75 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex 1 1.01 Male Ref Ref Female 1.02 1.01-1.03 Race 1 1.01 1.01 White Ref 0.93 0.93 Black 1.00 0.97-1.02 0.93-0.99 Asian 0.93 0.88-0.98 0.93 Native American 0.97 0.89-1.05 0.01 Other 1.00 0.95-1.04 0.95 Primary payer 1.12 1.01 1.02 Medicare Ref Ref 1.02 1.12 Private 1.00 0.98-1.02 1.12 1.12 1.12 No charge 1.18 1.02-1.36 1.02 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1 | 40-49 | 1.40 | 1.34-1.47 | |
| 60-69 2.10 1.99-2.22 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex Image 4.80 4.53-5.09 Sex Image 1.01 Image Image Male Ref= Image Imag | 50-59 | 1.66 | 1.58-1.75 | |
| 70-79 2.95 2.79-3.12 ≥ 80 4.80 4.53-5.09 Sex Male Referce Female 1.02 1.01-1.03 Race White Referce Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer 0.93 0.88-0.98 Medicare Referrce 0.97 Medicare 1.00 0.95-1.04 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 score (base 0) Respiratory dysfunction 1.12 Absent Referce 3.18-3.33 Cardiac dysfunction Referce 1.99 Absent Referce </td <td>60-69</td> <td>2.10</td> <td>1.99-2.22</td> | 60-69 | 2.10 | 1.99-2.22 | |
| ≥ 80 4.80 4.53-5.09 Sex I I Male Reference Female 1.02 1.01-1.03 Race I I White Reference Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer I I Medicare Reference Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 Score (base 0) 1.12 1.12-1.13 Respiratory dysfunction Reference Present 3.26 3.18-3.33 Cardiac dysfunction Reference Present 1.99 1.95-2.02 | 70-79 | 2.95 | 2.79-3.12 | |
| Sex Image Reference Male Reference Female 1.02 1.01-1.03 Race Image Image White Reference Image Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer Image Image Medicare Reference Reference Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score Image Image Respiratory dysfunction Image Image Absent Reference Image Present 3.26 3.18-3.33 Cardiac dysfunction Image | ≥ 80 | 4.80 | 4.53-5.09 | |
| Male Reference Female 1.02 1.01-1.03 Race 1.00 0.97-1.02 White Reference Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer Medicare Reference Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.13 Score (base 0) 1.12 1.12-1.13 Score (base 0) Index score Index score Present 3.26 3.18-3.33 Cardiac dysfunction Ref Index score Present 1.99 1.95-2.02 | Sex | | | |
| Female 1.02 1.01-1.03 Race I I White Reference Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer I I Medicare Reference Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.13 Score (base 0) I.12 1.12-1.13 Respiratory dysfunction Reference Present 3.26 3.18-3.33 Cardiac dysfunction Reference Absent Reference Present 1.99 1.95-2.02 | Male | Refe | rence | |
| Race Image: Reference White Reference Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer 1.00 0.95-1.04 Medicare Reference No charge Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 score (base 0) Respiratory dysfunction Reference Present 3.26 3.18-3.33 Cardiac dysfunction Reference Present Absent Reference Present Present 1.99 1.95-2.02 | Female | 1.02 | 1.01-1.03 | |
| White Reference Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer - - Medicare Reference - Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 Score (base 0) 2 1.12-1.13 Respiratory dysfunction 3.26 3.18-3.33 Cardiac dysfunction Reference Present 3.26 3.18-3.33 Cardiac dysfunction Reference Present 1.99 1.95-2.02 | Race | | | |
| Black 1.00 0.97-1.02 Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer | White | Refe | rence | |
| Hispanic 0.96 0.93-0.99 Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer Medicare Referme Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 Score (base 0) Respiratory dysfunction 3.26 3.18-3.33 Cardiac dysfunction Referme Absent Referme Present 3.26 3.18-3.33 Cardiac dysfunction 1.199 1.95-2.02 | Black | 1.00 | 0.97-1.02 | |
| Asian 0.93 0.88-0.98 Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer | Hispanic | 0.96 | 0.93-0.99 | |
| Native American 0.97 0.89-1.05 Other 1.00 0.95-1.04 Primary payer Medicare Referce Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.36 Other 1.12 1.12-1.36 Respiratory dysfunction 1.12 1.12-1.13 Respiratory dysfunction Referce 3.18-3.33 Cardiac dysfunction Referce 9 Absent Referce 9 Present 3.26 3.18-3.33 Cardiac dysfunction Referce 9 Present 1.99 1.95-2.02 | Asian | 0.93 | 0.88-0.98 | |
| Other 1.00 0.95-1.04 Primary payer | Native American | 0.97 | 0.89-1.05 | |
| Primary payer Image: Constraint of the sector | Other | 1.00 | 0.95-1.04 | |
| Medicare Reference Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.36 Each additional score (base 0) 1.12 1.12-1.13 Respiratory dysfunction 1.12 1.12-1.13 Absent Reference Present 3.26 3.18-3.33 Cardiac dysfunction Reference Present 1.99 1.95-2.02 | Primary payer | | | |
| Medicaid 1.09 1.06-1.12 Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 Score (base 0) 1.12 1.12-1.13 Respiratory dysfunction Reference 1.12 Present 3.26 3.18-3.33 Cardiac dysfunction Reference 1.99 Present 1.99 1.95-2.02 | Medicare | Refe | rence | |
| Private 1.00 0.98-1.02 Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.33 Each additional score (base 0) 1.12 1.12-1.13 Respiratory dysfunction 1.12 1.12-1.13 Absent Referme 1.12 Present 3.26 3.18-3.33 Cardiac dysfunction Referme 1.99 Present 1.99 1.95-2.02 | Medicaid | 1.09 | 1.06-1.12 | |
| Self-pay 1.32 1.25-1.39 No charge 1.18 1.02-1.36 Other 1.20 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.29 Charlson comorbidity index score 1.12 1.12-1.13 Score (base 0) 1.12 1.12-1.13 Respiratory dysfunction Reference 1.12 Absent Reference 1.12 Present 3.26 3.18-3.33 Cardiac dysfunction Reference 1.99 Present 1.99 1.95-2.02 | Private | 1.00 | 0.98-1.02 | |
| No charge1.181.02-1.36Other1.201.12-1.29Charlson comorbidity index score1.121.12-1.29Each additional score (base 0)1.121.12-1.13Respiratory dysfunction1.121.12-1.13AbsentReferencePresent3.263.18-3.33Cardiac dysfunctionReferenceAbsentReferencePresent1.991.95-2.02 | Self-pay | 1.32 | 1.25-1.39 | |
| Other1.201.12-1.29Charlson comorbidity index score1.121.12-1.13Each additional score (base 0)1.121.12-1.13Respiratory dysfunction1.121.12-1.13AbsentReferencePresent3.263.18-3.33Cardiac dysfunctionReferenceAbsentReferencePresent1.991.95-2.02 | No charge | 1.18 | 1.02-1.36 | |
| Charlson comorbidity index scoreImage: Charlson comorbidity index scoreImage: Charlson comorbidity index scoreEach additional score (base 0)1.121.12-1.13Respiratory dysfunction1.121.12-1.13Respiratory dysfunctionImage: Charlson comorbidityImage: Charlson comorbidityAbsentReferencePresent3.263.18-3.33Cardiac dysfunctionImage: Charlson comorbidityAbsentReferencePresent1.991.95-2.02 | Other | 1.20 | 1.12-1.29 | |
| Each additional score (base 0)1.121.12-1.13Respiratory dysfunction1.121.12-1.13AbsentReferencePresent3.263.18-3.33Cardiac dysfunction3.263.18-3.33Cardiac dysfunctionReferencePresent1.991.95-2.02 | Charlson comorbidity index score | | | |
| Respiratory dysfunctionReferenceAbsentReferencePresent3.263.18-3.33Cardiac dysfunctionAbsentReferencePresent1.991.95-2.02 | Each additional score (base 0) | 1.12 | 1.12-1.13 | |
| AbsentReferencePresent3.263.18-3.33Cardiac dysfunctionAbsentReferencePresent1.991.95-2.02 | Respiratory dysfunction | | | |
| Present3.263.18-3.33Cardiac dysfunctionAbsentReferencePresent1.991.95-2.02 | Absent | Refe | rence | |
| Cardiac dysfunction Absent Present 1.99 1.95-2.02 (Continued) | Present | 3.26 | 3.18-3.33 | |
| Absent Reference Present 1.99 1.95-2.02 (Continued) | Cardiac dysfunction | | | |
| Present 1.99 1.95-2.02 | Absent | Reference | | |
| (Continued) | Present | 1.99 | 1.95-2.02 | |
| | | | (Continued) | |

TABLE 3] Predictors of Mortality in Patients With Severe Sepsis

TABLE 3] (Continued)

| Characteristic | OR | 95% CI | |
|---|-----------|-----------|--|
| Renal dysfunction (acute kidney injury) requiring dialysis | | | |
| Absent | Refe | rence | |
| Present | 1.56 | 1.51-1.61 | |
| Hepatic dysfunction | | | |
| Absent | Reference | | |
| Present | 1.96 | 1.92-2.00 | |
| Hematologic dysfunction | | | |
| Absent | Refe | rence | |
| Present | 1.35 | 1.33-1.38 | |
| Metabolic dysfunction | | | |
| Absent | Refe | rence | |
| Present | 1.63 | 1.61-1.66 | |
| Neurologic dysfunction | | | |
| Absent | Refe | rence | |
| Present | 1.20 | 1.17-1.23 | |
| Mechanical ventilation use | | | |
| Absent | Refe | rence | |
| Present | 1.38 | 1.35-1.42 | |
| Hospital teaching status | | | |
| Non-Teaching | Refe | rence | |
| Teaching | 1.19 | 1.14-1.24 | |
| Hospital bed size | | | |
| Small | Refe | rence | |
| Medium | 1.03 | 0.98-1.08 | |
| Large | 1.13 | 1.07-1.20 | |
| Hospital volume | | | |
| Small | Reference | | |
| Medium | 0.86 | 0.83-0.90 | |
| Large | 0.78 | 0.73-0.82 | |
| Hospital location | | | |
| Rural | Reference | | |
| Urban | 0.94 | 0.90-0.99 | |
| Hospital region | | | |
| Northeast | Reference | | |
| Midwest | 0.65 | 0.61-0.69 | |
| South | 0.80 | 0.76-0.84 | |
| West | 0.77 | 0.73-0.81 | |
| Year of admission | | | |
| Each additional year (base 2000) | 0.89 | 0.89-0.89 | |

nonteaching hospitals, although it was somewhat lower in teaching hospitals. The most likely explanation for the observed differences in mortality is variation in severity of illness—a hypothesis supported by our findings of increased organ failures, septic shock, burden of comorbid disease, and receipt of mechanical ventilation in the culture-negative cohort. It is possible that this increased severity of illness may have been manifested at the inception of severe sepsis, prompting clinicians to administer antibiotics early without performing appropriate cultures, leading to culture-negative status. Other possible reasons may include a delay in, or shorter duration of, antibiotic therapy or potentially inappropriate antibiotic therapy for lack of guidance from specific cultures. As inappropriate or inadequate antibiotic therapy has been associated with higher mortality in patients with severe sepsis,²¹⁻²³ this could translate into increased mortality seen in the CNSS cohort. It is also plausible that at least a few of the patients with CNSS had culture-negative status, as they had already received antibiotics prior to the episode of severe sepsis. Prior antibiotic exposure can, on one hand, translate into culture-negative status and, on the other hand, could lead to decreased antimicrobial susceptibility and increased mortality.²⁴ It is also plausible that severe sepsis goes unrecognized in patients with culture-negative status until later in the course of hospitalization, which could therefore contribute to the worse outcomes seen. We were unable to explore this hypothesis for lack of relevant data, but it should be a focus of future research studies.

Our study has several important limitations. We have relied on ICD-9-CM codes to identify patients with severe sepsis. Although our codes to identify severe sepsis are in line with those used in the literature,^{2,4,16} it is important to keep in mind their limitations and evolution through the years. Specific codes for severe sepsis and septic shock were introduced in 2002 and 2003, respectively. Observing consistent trends over the years, however, mitigates concerns regarding the impact of ICD-9-CM codes. Although the time frame of the study spans both before and after the Surviving Sepsis Campaign guidelines, but as the management practices for all patients with sepsis (both CNSS and CPSS) should still be similar in each era, it should not have impacted our results. This is also evident from the regression analysis in which the interaction term between the variable for CNSS and the year of admission was not significant (P = .3). In addition, when the data were analyzed in two separate eras (2000-2002 and after

2002), CNSS continued to be an independent predictor of mortality in both eras (e-Tables 10, 11). Our data sources did not allow us to capture processes of care and details of the acute illness such as vital signs, laboratory data, drug administration, timeliness of antibiotic therapy, appropriateness of cultures, and timing of source control. If available, inclusion of these variables in our multivariable model would have added to the robustness of our results. Our data sources also may have limited our ability to properly classify infections that may have been diagnosed with newer technologies, such as polymerase chain reaction. If not captured by ICD-9-CM codes, such infections would potentially be misclassified in the CNSS cohort. Similarly, it is also possible that some patients with CNSS may, in fact, have had a noninfectious SIRS and associated organ failure. The NIS database does not have complete data on patient race, which limits our ability to interpret and explore the impact of race on our outcomes. We did, however, perform a sensitivity analysis by including missing values of race as a separate category to evaluate if our missing data handling technique impacted our results; yet we found similar results. In addition, we did not have sufficient information to describe geographic variations in epidemiology and outcomes of CNSS. Further studies specifically looking into this aspect with more granular data are needed. The database also does not provide any information about readmissions. We did, however, determine the similar admissions based on patient, primary payer, and hospital characteristics as potential readmissions and found the same increasing trend of CNSS admissions and their impact on mortality. Patients who die before their cultures have had a chance to become positive can be mislabeled as having a culture-negative status. As the majority of cultures should become positive by day 3,²⁵ we performed another sensitivity analysis by including only those who survived by day 3 of hospital admission and found having negative culture results was still an independent predictor of mortality. To further explore if acute cardiac dysfunction by itself could explain CNSSassociated increased mortality, we performed another sensitivity analysis by excluding all those with acute cardiac dysfunction and found that culture-negative status continued to be an independent predictor of death. To account for differences in the baseline characteristics of CNSS and CPSS, we generated a propensity score matched cohort (e-Fig 1) and found that having culture-negative status was still an independent predictor of mortality. Thus, although this study has the limitations of any study performed using administrative

data sets, we have shown the robustness of our results by performing multiple sensitivity analyses.

Despite its limitations, our findings indicate that CNSS constitutes a substantial proportion of patients with severe sepsis. Clinicians should be cognizant that patients with CNSS have a greater severity of illness and succumb to their illness more often than their culturepositive counterparts. Our study also provides important directions for future research. Investigators should view persons with CNSS as a distinct cohort of patients who may respond differently to therapeutic interventions. Reasons for the growing incidence and worse associated outcomes of CNSS should be the focus of future studies.

Acknowledgements

Author contributions: A. S. takes responsibility for the content of the manuscript, including the data and analysis. S. G., A. S., and K. B. K. made substantial contributions to the conception and design of the study. S. G., A. S., S. G., G. K., E. M., R. S. N., and K. B. K. made substantial contributions to analysis and interpretation of data. S. G. drafted the initial manuscript. All authors revised the manuscript critically for important intellectual content and provided final approval for the version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Financial/nonfinancial disclosures: None declared.

Additional information: The e-Appendix, e-Figures, and e-Tables can be found in the Supplemental Materials section of the online article.

References

- Melamed A, Sorvillo FJ. The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. *Critical Care*. 2009;13(1):R28.
- 2. Kumar G, Kumar N, Taneja A, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). *Chest.* 2011;140(5):1223-1231.
- 3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med.* 2003;31(4): 1250-1256.
- Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med.* 2003;348(16):1546-1554.
- Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med.* 2006;34(6):1589-1596.

- Blanco J, Muriel-Bombin A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. *Crit Care*. 2008;12(6):R158.
- Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med.* 2006;34(2):344-353.
- 8. Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med.* 2004;30(4):580-588.
- **9.** Martin CM, Priestap F, Fisher H, et al. A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. *Crit Care Med.* 2009;37(1):81-88.
- Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
- Redondo MC, Arbo MD, Grindlinger J, Snydman DR. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1995;20(6):1492-1496.
- Cohen J, Cristofaro P, Carlet J, Opal S. New method of classifying infections in critically ill patients. *Crit Care Med.* 2004;32(7):1510-1526.
- Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB. Variations in organism-specific severe sepsis mortality in the United States: 1999-2008. *Crit Care Med.* 2015;43(1):65-77.
- Phua J, Ngerng W, See K, et al. Characteristics and outcomes of culturenegative versus culture-positive severe sepsis. *Crit Care*. 2013;17(5):R202.
- Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project-HCUP A Federal-State-Industry Parnership in Health Data. Introduction to the HCUP Nationwide Inpatient Sample 2009. http://www.hcup-us.ahrq.gov/db/ nation/nis/NIS_2009_INTRODUCTION. pdf. Accessed January 18, 2015.

- Sakhuja A, Kumar G, Gupta S, Mittal T, Taneja A, Nanchal RS. Acute kidney injury requiring dialysis in severe sepsis. *Am J Respir Crit Care Med.* 2015;192(8):951-957.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
- Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. *Healthy People 2000 Stat Notes*. 2001;(20):1-9.
- Ferrer R, Artigas A, Levy MM, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. *JAMA*. 2008;299(19):2294-2303.
- 20. Yokota PK, Marra AR, Martino MD, et al. Impact of appropriate antimicrobial therapy for patients with severe sepsis and septic shock—a quality improvement study. *PloS One.* 2014;9(11):e104475.
- Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest.* 1999;115(2):462-474.
- 22. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. *Am J Med.* 2003;115(7):529-535.
- 23. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. *Crit Care Med.* 2003;31(12):2742-2751.
- Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. *Crit Care Med.* 2011;39(8):1859-1865.
- Bourbeau PP, Pohlman JK. Three days of incubation may be sufficient for routine blood cultures with BacT/Alert FAN blood culture bottles. J Clin Microbiol. 2001;39(6):2079-2082.